Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
COPD is characterised by inflammation of the lower airways and destruction of lung tissue that limit airflow and lung function. One of the major causes of disease progression, for which there are no effective treatments, is excess inflammatory mucus that blocks airways and prevents normal breathing.
The research, due to be published in the Journal of Clinical Investigation in September, shows that viruses could be a significant risk factor for COPD. Viruses can affect the cells that line the airways, leading to the long-term lung inflammation and mucus production that is typical of COPD.
The researchers explored the relationship between the short-term duration of most viral infections and long-term chronic inflammatory diseases such as COPD. They knew that a molecule called interleukin-13 (IL-13) was the key driver of excess production of chronic airway mucus after viral infection and traced the source of IL-13 to cells in the immune system. But until now, they did not know how this type of immune response could cause a long-term disease like COPD.
Michael J. Holtzman, MD, lead researcher, believes that monitoring IL-13 production will allow doctors to identify which patients would benefit from strategies to interrupt this process in the body and prevent the advancement of COPD. “We also provided the initial evidence that an additional stress or danger, such as smoking or pollution or even another infection, could cause these cells to release IL-33, which then stimulates immune cells to produce IL-13 and in turn the airway mucus typical of COPD and related respiratory diseases. It’s also possible that smoke exposure predisposes individuals to the development of these cells and, in turn, the susceptibility to exacerbation and progression of this type of disease.”
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description